Robert Ostendorf
Functie:
Senior Business Development Manager translational pharmaceutical research
I am passionate about TNO’s unique expertise in translational (preclinical) research. My work focuses on efficacy, ADME/DMPK and target safety of new pharmaceutical interventions, with special interest in cardiovascular, metabolic and fibrotic diseases, and biomarker research.
Looking for contract research support, or see opportunities for collaboration? Please, reach out.
Topics you can approach me about
I support biotech, pharma and academic partners in accelerating their R&D with TNO’s translational models, functional biomarker platforms and advanced ADME/DMPK solutions.
- Translational efficacy models – Cardiometabolic and fibrotic diseases (MASLD/MASH, CKD, obesity), neuro‑inflammation & brain health (incl. Ldlr-/-.Leiden), and Women’s Health, using validated in vivo and in vitro models with strong predictive value.
- Biomarkers & advanced tissue analytics – Mechanistically causal, functional biomarkers for patient stratification, target engagement and early efficacy readouts; supported by spatial omics and mass‑spec imaging.
- ADME/DMPK & microtracer (AMS) – Early human‑relevant PK, target exposure and absorption insights, including InTESTine™ intestinal permeability models for small molecules and beyond rule of five compounds.
- Organ‑on‑Chip / MPS – Collaboration on scalable and cost‑effective OoC development and validation, together with TNO‑Holst expertise
- AI‑enabled early target evaluation – Integrating omics, imaging and machine‑learning pipelines to improve early decision‑making.
- Collaboration formats include contract research, PPP consortia, and co‑development/IP‑based partnerships, backed by strong project management.
- Exploring a PoC, validation study or new consortium?
Feel free to reach out; I’m happy to discuss how TNO’s models and technologies can strengthen your development pipeline.